Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dondorp AM, Fanello CI, Hendriksen ICE, et al, for the AQUAMAT group. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376: 1647–57—In this Article (Nov 13), the row in table 2 for death or sequelae at 28 days in the quinine group should have been: 316/2695 (11·7%). In table 1, the data in parentheses for coma depth are IQR. The last line of the legend for figure 3 should have read: “I2 denotes the percentage of total variation across subgroups resulting from heterogeneity rather than chance, with the p value of significance”. The title of figure 5 should have read: “Meta-analysis of all randomised controlled trials that have compared mortality of severe malaria in patients treated with parenteral artesunate versus parenteral quinine12–16”. These corrections have been made to the online version as of Jan 7, 2011.

Original publication




Journal article


The Lancet

Publication Date